If you or a loved one is taking Tysabri, you may wonder about the risk of progressive multifocal leukoencephalopathy (PML) and what monitoring is needed. The medical community has long emphasized the importance of risk-benefit analysis in disease-modifying therapies, and for Tysabri, that means regular follow-up with MRI and other tests. This page explains who requires monitoring, what tests are used, and how often they should occur.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the John Cunningham virus (JCV). For patients in North Carolina who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label emphasizes that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically presents with progressive neurological deficits such as cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. The clinical course is often devastating, with most patients experiencing severe disability or death. The Tysabri label notes that healthcare professionals "should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JCV to reactivate and cause lytic infection of oligodendrocytes. This immunosuppressive effect is compounded in patients with prior immunosuppressant use or prolonged Tysabri exposure. The label states that Tysabri "increases the risk of PML" and that this risk is "an opportunistic viral infection of the brain" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a legal perspective, patients in North Carolina who have developed PML after Tysabri use may have claims related to inadequate warnings. The boxed warning clearly states the risk, but questions may arise about whether healthcare providers and patients were adequately informed about the magnitude of risk, especially in patients without prior immunosuppressant use or with shorter treatment durations. The label also notes that Tysabri is "available only through a restricted distribution program called the TOUCH Prescribing Program" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which includes patient education and monitoring requirements. Failure to adhere to these program requirements could be relevant to a claim.
The statute of limitations for product liability claims in North Carolina is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. The label reports that herpes infections have occurred "from a few months to several years" after starting Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and PML risk similarly increases with treatment duration. Patients should be aware that the clock for the statute of limitations may start when PML is diagnosed or when symptoms first appear, whichever is earlier. Consulting with an attorney experienced in pharmaceutical litigation is essential to determine the applicable deadline based on individual circumstances. In summary, Tysabri carries a known risk of PML, a severe and often fatal brain infection. For North Carolina patients affected by this complication, the medical evidence supports a clear causal link, and legal options may exist if warnings were inadequate or if monitoring protocols were not followed. Prompt legal consultation is advised to preserve any potential claims within the statute of limitations.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For PML, this may start at diagnosis or when symptoms first appear. It is crucial to consult an attorney promptly to determine the exact deadline for your case.
The Tysabri label identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.